Carboplatin (paraplatin)
Most commonly used for the treatment of ovarian and lung cancer, Bristol Myers Squibb’s carboplatin has also been used to treat sufferers of pleural malignant mesothelioma, usually in tandem with the drug gemcitabine.
Classified as a DNA alkylating agent, this drug was first used in the late 1980s. It carries far fewer side effects than its parent compound, cisplatin. According to experts, this is due to the added stability of carboplatin in the bloodstream, which prevents proteins from binding to it, allowing it to remain in the body for a longer period of time. The flipside is that it takes larger doses in order for carboplatin to be as effective as cisplatin.
Treatment with Carboplatin
Mesothelioma patients that are treated with carboplatin or a combination of carboplatin and another chemo drug should be abreast of all the specifics of the drug, including how it is administered and other specifics.
- Carboplatin is a clear liquid that may be given intravenously.
- The drug can also be administered through a central line near the collarbone or in the crook of the arm.
Possible Side Effects of Carboplatin
Thank you for visiting this website which is sponsored by the Law Firm of EARLY, LUDWICK, SWEENEY & STRAUSS, LLC. This website is devoted to the needs of people diagnosed with mesothelioma. The content contained herein was not prepared by medical professionals nor should it be taken as a substitute for medical advice. Additionally, this information is not intended to create an attorney-client relationship simply by its viewing. The creation of an attorney-client relationship requires more than viewing this or affiliated websites. Neither the transmission nor receipt of this website material will create an attorney-client relationship between sender and receiver. The material contained herein is general in nature and may not apply to your particular factual or legal circumstances. Online readers should not act on this information without seeking professional counsel. Please read our
disclaimer for more information.